The Science Behind Artemis
Accelerating Discovery at an Unprecedented Scale
Artemis Therapeutics was founded by Dr. Artem Cherkasov and Dr. Mads Daugaard to harness more than three decades of pioneering research in molecular modelling, machine learning, and functional drug validation.
The company was built around a simple but powerful idea: drug discovery does not need to move at the speed it has for the past 50 years.
At the heart of Artemis is DeepDocking®, the world’s first AI-accelerated docking platform, pioneered by Dr. Cherkasov. DeepDocking® fundamentally redefined how structure-based drug discovery is performed — enabling up to 6,000-fold acceleration in virtual screening of drug candidates compared to traditional methods.
What once required years of computational effort can now be achieved in days.
A Proven Drug Discovery Platform
Artemis is not theoretical AI. It is a validated engine for real-world drug discovery.
Using the Artemis platform:
- Six drug candidates have been identified and licensed to pharmaceutical companies
- These deals include the largest licensing transaction by a Canadian university, valued at $142M
- During the COVID-19 pandemic, the platform screened 1.4 billion compounds in just 19 days, identifying viable prospective therapeutic candidates
- Research groups led by Dr. Cherkasov have won two international CACHE drug discovery competitions (COVID-19 and Parkinson’s targets in 2024 and 2025)
The platform has demonstrated both scientific rigor and commercial relevance.
A Proven Drug Discovery Platform
Artemis is not theoretical AI. It is a validated engine for real-world drug discovery.
Using the Artemis platform:
- Six drug candidates have been identified and licensed to pharmaceutical companies
- These deals include the largest licensing transaction by a Canadian university, valued at $142M
- During the COVID-19 pandemic, the platform screened 1.4 billion compounds in just 19 days, identifying viable prospective therapeutic candidates
- Research groups led by Dr. Cherkasov have won two international CACHE drug discovery competitions (COVID-19 and Parkinson’s targets in 2024 and 2025)
The platform has demonstrated both scientific rigor and commercial relevance.
Beyond DeepDocking®: A Next-Generation AI Platform
Building on its foundational DeepDocking® technology, Artemis has developed the next evolution of AI-driven discovery:
DeepDocking®-Lightning
Enables an additional 20–100X acceleration compared to the original DeepDocking® platform — dramatically expanding screening throughput and reducing time-to-insight.
DeepDocking®-Ultra
A next-generation AI platform designed to enable structure-based drug discovery at genome-wide scale, expanding target coverage and enabling systematic, scalable discovery across vast biological landscapes.
Together, these technologies form a vertically integrated computational discovery stack — from large-scale screening to candidate nomination.
An Asset-Driven Biopharma Model
Artemis is not an AI service provider.
The company operates as an asset-driven biopharma company, using its proprietary platform to generate and advance its own drug candidates. This model allows Artemis to capture the full upside of the assets it creates — translating computational breakthroughs into clinical and commercial value.
Artificial intelligence is the engine.
Drug candidates are the outcome.
Patients are the purpose.
Let's Advance Discovery Together
If you are interested in partnering, investing, or exploring scientific collaboration, we welcome the conversation.